Latest News and Press Releases

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...

MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...

Burlingame, April 08, 2024 (GLOBE NEWSWIRE) -- The Global Telehealth Services Market in terms of revenue was estimated to be worth $12.47 billion in 2023 and is poised to reach $26.64 billion by...

The 5th edition explores some IRA implications on biosimilars along with latest price trends, biosimilars market share Marks one year of providing quarterly updates on US biosimilar market trends ...

Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Global Surgical Sealants and Adhesives Market Size, Share & Trends Analysis Report by Type (Natural Or Biological, Synthetic and Semi Synthetic),...

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery (ASCRS) while topline readout from the second Phase 3 OPTIMIZE-2...

Lannion, 05/04/2024 - 17h45 LUMIBIRD: PUBLICATION OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE ANNUAL FINANCIAL REPORT LUMIBIRD announces that it has filed its 2023 Universal...

EXTON, PA, April 05, 2024 (GLOBE NEWSWIRE) -- As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra...